

To: (10)(2e) <(10)(2e)@minvws.nl>; (10)(2e) <(10)(2e)@minvws.nl>
Cc: (10)(2e) <(10)(2e)@minvws.nl>; (10)(2e) <(10)(2e)@minvws.nl>
From: (10)(2e)
Sent: Fri 4/17/2020 11:28:28 AM
Subject: FW: HSC Audio meeting 15/4/20 terugkoppeling en conceptverslag
Received: Fri 4/17/2020 11:28:28 AM
[Evaluation phases \(10\)\(2e\) and serology POCT 20200417.docx](#)
[validatie rapport RIVM sneltesten final VS 2.0 12042020.pdf](#)

Ha (10)(2e) en (10)(2e),

Hierbij de eerste informatie Nav het actiepunt vanuit hsc meeting mbt validatie lab equipment. Mogelijk volgt later nog meer.

Groet,

(10)(2e)

Verzonden met BlackBerry Work
 (www.blackberry.com)

Van: (10)(2e) <(10)(2e)@rivm.nl>
Datum: vrijdag 17 apr. 2020 1:21 PM
Aan: (10)(2e) <(10)(2e)@minvws.nl>
Kopie: (10)(2e) <(10)(2e)@rivm.nl>, (10)(2e) <(10)(2e)@rivm.nl>
Onderwerp: RE: HSC Audio meeting 15/4/20 terugkoppeling en conceptverslag

Beste (10)(2e),

Uit naam van (10)(2e) beantwoord ik deze mail vanuit de werkgroep serologie.

Bijgevoegd is een overzicht van de status van de evaluaties die in Nederland worden uitgevoerd voor (10)(2e) testen en serologische sneltesten (POCT).

Ook bijgevoegd is het rapport met evaluatie resultaten van het RIVM mbt de sneltesten. Het rapport met validaties van (10)(2e) is volgende week klaar.

Voor het delen van validatierapporten van andere laboratoria (niet allemaal in het Engels) zijn we op dit moment toestemming aan het vragen, deze kunnen mogelijk later gedeeld worden.

De status en resultaten van de moleculaire tests volgen later.

Met vriendelijke groet,

(10)(2e)

From: (10)(2e) <(10)(2e)@rivm.nl> On Behalf Of (10)(2e)
Sent: vrijdag 17 april 2020 10:05
To: (10)(2e) <(10)(2e)@rivm.nl>
Cc: (10)(2e) <(10)(2e)@rivm.nl>
Subject: FW: HSC Audio meeting 15/4/20 terugkoppeling en conceptverslag

Hi (10)(2e), beantwoordt jij deze mail of is er iets nodig van (10)(2e)?

Groet, (10)(2e)

Van: (10)(2e) <(10)(2e)@minvws.nl>
Verzonden: donderdag 16 april 2020 08:43
Aan: (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) <(10)(2e)@rivm.nl>
CC: (10)(2e) <(10)(2e)@minvws.nl>; (10)(2e) <(10)(2e)@minvws.nl>; (10)(2e) <(10)(2e)@minvws.nl>
Onderwerp: FW: HSC Audio meeting 15/4/20 terugkoppeling en conceptverslag

Hoi (10)(2e) en (10)(2e).

Zie bericht hieronder, actiepoint onderaan bij laboratory testing.

Kunnen jullie ons van informatie voorzien over de validaties die jullie momenteel uitvoeren, liefst in Engels? Dank!

Groet,

(10)(2e)

Verzonden met BlackBerry Work

(www.blackberry.com)

Van: (10)(2e) <(10)(2e)@minvws.nl>

Datum: woensdag 15 apr. 2020 11:28 PM

Aan: Coronateam PG <(10)(2e)@minvws.nl>, Dienstpostbus DCC-VWS <(10)(2e)@minvws.nl>, (10)(2e) <(10)(2e)@minvws.nl>, (10)(2e) <(10)(2e)@minbuza.nl>, (10)(2e) <(10)(2e)@minvws.nl>, coronaGMT <(10)(2e)@minvws.nl>, (10)(2e) <(10)(2e)@minvws.nl>, (10)(2e) <(10)(2e)@minvws.nl>, (10)(2e) <(10)(2e)@rivm.nl>, (10)(2e) <(10)(2e)@rivm.nl>, (10)(2e) <(10)(2e)@rivm.nl>, (10)(2e) <(10)(2e)@minvws.nl>, (10)(2e) <(10)(2e)@minvws.nl>

Onderwerp: HSC Audio meeting 15/4/20 terugkoppeling en conceptverslag

Dag allen,

Vandaag was weer een HSC audiomeeting. Bijgaand de belangrijkste punten, in de bijlage het verslag van de HSC voor meer informatie. In de bijlage ook (nogmaals) enkele belangrijke documenten. Graag aandacht voor de actiepunten.

- Update on forthcoming emergency support instrument (ESI)
 - o ESI was proposed a few weeks ago by the commission. Approved by the council yesterday, budget to be approved by the European parliament later this week.
 - o The idea is that ESI provides a flexible crisis instrument to complement those that already exist in MS and within the Commission.
 - o The Integrated Political Crisis Response platform as well as the Health Security Committee and the Civil Protection Committee will act as the central fora for engagement with Member States for this instrument.
 - o It will be used during the acute, exit and recovery phase of the outbreak.
 - o It will have a budget of 2.7 billion Euros; a further 300 million euros are foreseen for the medical stockpiling of rescEU.
 - o For examples of possible uses of ESI, depending on the needs of MS please refer to the presentation in the attachment.
 - o Clearing house is working on identifying supply and needs with regard to medical equipment. As countries will all be in different phases of the pandemic, some of the material no longer needed in countries in exit phase can be shifted to counties entering the acute phase.
- Convalescent plasma collection and transfusion for COVID-19
 - o The work concerns the experimental therapy of plasma where there are antibodies, for transfusion that can be taken from donors that are COVID-19 recovered patients.
 - o This practice has already started in some countries, proposal is to start large-scale clinical trials that would provide the basis for evidence of its utility and benefits.
 - o The Commission will set up a platform to exchange and input data, as well as ensuring fast access the therapy, should it prove useful. In addition, the Commission is providing guidance, developed with all national authorities, that considers how the therapy can be used, common protocols for collection and use and what kind of outcome data should be monitored.
 - o Problems so far include the fact that clinical trials currently under way are not all aligned in protocols, making comparison of results at a later stage difficult. Additional complication is that plasma collection is done differently in MS.
- Laboratory testing
 - o Discussion was mostly about the validation of tests.
 - o Compliance with IVDD/IVDR for devices developed for COVID-19 is not yet required but very much encouraged. Performance valuation is done by manufacturer, additional evaluation is not required but encouraged.
 - o As devices for COVID-19 were developed very quickly it is important to do additional validation in blood tests and clinical studies of these tests because there are no reference devices.
 - o On 15 April, the Commission published Guidelines on COVID-19 in vitro diagnostic tests and their performance .

- o Another working document under preparation aims to stimulate discussions and includes a literary review of the data and propositions for performance criteria.
- o France advised that they are also evaluating and assessing the performance of serological tests and will soon share with the Health Security Committee the first results of the assessment.
- o The Commission is now collecting information on validation studies that are already under way
- o It will help to have a standardized panel to validate all tests.

ACTIEPUNT: Please inform the HSC on what validations for tests are being done and what panels/set ups are being used? @RIVM en (10)(2e) – graag input hiervoor

- Digital solutions in health care – mobile apps

- o The Commission presented the ongoing work regarding the toolbox on mobile applications to support contact tracing and warning and in the EU's response to COVID-19. For more detailed information please contact the eHealth Network ((10)(2e)) or (10)(2e) (DI))
- o An app will be a useful addition but not replacement of current contact tracing strategies.

ACTIEPUNT: Please answer the questions in writing regarding the toolbox and mobile apps and connect with eHealth members – VOLDAAN voor input NL afgestemd met DI en RIVM zie mail in de bijlage

- Exit strategies

- o The ECDC noted their last risk assessment and their surveillance strategy document as reference documents for countries in their approach to de-escalation of measures.
- o ECDC noted that as per their own assessments, there is *no indication* that we have reached the peak of the epidemic yet and that lifting of any measures needs to be based on scientific evidence and knowledge of the situation so to avoid any overwhelming of health systems.
- o The Commission highlighted the Joint European Roadmap towards lifting COVID-19 containment measures published on 15 April, which should also be taken into consideration by Member States (please find the roadmap as well as the factsheet for the roadmap attached)
- o The Netherlands noted that measures would remain in place until the 28th of April, public events cancelled until June and that, at this stage, it is too early to relax measures and that pressure on health systems remains elevated.

ACTIEPUNT: The Commission reiterated the importance of sharing of information by countries and as such asked for written input from the members. Including any plans for lifting measures, including criteria for such actions and monitoring/surveillance in place by MS. HSC will synthesize and compile an overview of measures of all MS. HSC will provide a table for MS to fill in regarding exit strategy measures, please include detailed descriptions of measures, not only high level input. @RIVM – graag tzt jullie input voor de tabel.

- Update on joint procurement

- o We are expecting a new JP snapshot update this week, most recent (08-04 attached)
- o Orders can be placed for PPE1 and PPE2
- o One company producing gloves for PPE1 turned in a revised proposal after the initial proposal which does not at all cover the needs of MS.
- o Ventilators: The first orders for ventilators can be placed
- o Lab equipment: deadline for proposals was 12 april, 33 out of 92 lots have been filled after contacting over 600 companies.

Er komen deze week nog:

- HSC audiomeeting mn ter bespreking van exit strategieën, datum en tijd volgen.
- Joint Procurement agreement steering committee overleg, datum en tijd volgen.

Groet,

(10)(2e)



(10)(2e)

Ministerie van Volksgezondheid, Welzijn en Sport

Directie Publieke Gezondheid | Crisisbeheersing en Infectieziekten
Parnassusplein 5 | 2511 VX | Den Haag
Postbus 20350 | 2500 EJ | Den Haag

06 (10)(2e)
(10)(2e)@minvws.nl | www.rijksoverheid.nl

Van: (10)(2e) @ec.europa.eu <(10)(2e) @ec.europa.eu>

Verzonden: woensdag 15 april 2020 18:33

Aan: (10)(2e) @ec.europa.eu

Onderwerp: Draft report HSC Audio meeting 15/4/20

Dear Members of the Health Security Committee,
Dear colleagues,

Please find attached the draft public report from today's audio meeting.

Please send us any comments by 16 April 15:00.

Kind regards,
HSC Secretariat

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.
www.rivm.nl/en Committed to health and sustainability